AFFILIATIONS
1 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
2 CTC Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Henan Cancer Hospital, Zhengzhou, Henan, China
4 Mianyang Central Hospital, Mianyang, Sichuan, China
5 Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
6 The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
7 Xiangya Hospital of Central South University, Changsha, Hunan, China
8 Xiangya Hospital of Central South University, Changsha, Hunan, China
9 Affiliated Hospital of Hebei University, Baoding, Hebei, China
10 Peking University Third Hospital, Beijing, Beijing, China
11 The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
12 The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
13 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
14 Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
15 Shandong Cancer Hospital, Ji'nan, Shandong, China
16 Shandong Cancer Hospital, Ji'nan, Shandong, China
17 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
18 The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
19 Anhui Provincial Cancer Hospital, Hefei, Anhui, China
20 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS), Tianjin, Tianjin, China
21 Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
22 The Third People's Hospital of Chengdu, Chengdu, Sichuan, China
23 Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
24 The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
25 The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
26 Hubei Provincial Cancer Hospital, Wuhan, Hubei, China
27 Qilu Hospital of Shandong University, Qingdao, Shandong, China
28 Nanyang Central Hospital, Nanyang, Henan, China
29 Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
30 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
31 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
32 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
33 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
34 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
35 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
36 Shanghai Helioson Pharmaceutical Co., Ltd., Shanghai, Shanghai, China
37 Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University., Chengdu, Sichuan, China, National Facility for Translational Medicine (Sichuan), West China Hospital, Chengdu, Sichuan, China, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan, China
ABSTRACT
Introduction: HP-001 is a novel oral IKZF1/3 molecular glue degrader. Pre-clinically, HP-001 demonstrated superior in vivo anti-tumor efficacy as mono-agent compared to mezigdomide, together with optimized in vitro hematologic safety compared to mezigdomide and cemsidomide (Wang D, et al. HemaSphere, 2025;9:[S1]:2866-2867). An ongoing phase 1 clinical trial (CTR20242943) is evaluating HP-001 alone for MM and NHL. Here we report preliminary results from the phase 1 study in pts with pretreated R/R MM.
Methods: CTR20242943 is an open-label, phase 1, multi-center, first-in-human study evaluating safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of HP-001 in patients (pts) with MM and non-Hodgkin’s lymphoma who have relapsed from and/or are refractory to standard of care options. The primary objective of this study is to characterize the safety and tolerability of HP-001 and to determine the maximum tolerated dose (MTD) and recommended doses for phase 2. Secondary objectives include assessments of anti-tumor activity according to the International Myeloma Working Group (IMWG) and Lugano response criteria, PK, and PD. Dose-escalation will start with an accelerated titration phase, followed by a Bayesian Optimal Interval (BOIN) design and a provision for additional pts to be enrolled in expansion cohorts at 2-3 selected dose levels. HP-001 will initially be orally administrated once daily on days 1-14 of each 28-day cycle, with doses ranging from 0.05 mg to 0.6 mg. Additional dosing schedules may be explored.
Results: As of May 30th, 2026 (median follow-up 6.80 months), 23 Chinese pts (17 R/R MM, 6 NHL) received HP-001: median age was 58 y (range 43-74), 16 (69.6%) were male. Pts had received a median of 3.5 prior lines of therapy (range 1-7). Among all pts with MM, prior therapies included IMiDs (100%; pomalidomide: 82%), PIs (94%), and anti-CD38 therapy (29%), with 29% being triple-refractory. Additionally, 5 pts had undergone ASCT, 3 had received CART therapy, and 2 presented with extramedullary disease (EMD).
HP-001 doses explored in dose-escalation and expansion cohorts included 0.05 mg (n=1), 0.1 mg (n=3), 0.2 mg (n=3), 0.4 mg (n=5), and 0.6 mg (n=3) with a 14 day on/14 day off dosing schedule. Additionally, a 10 day on/18 day off schedule was explored with 0.4 mg (n=1) and 0.6 mg (n=7). As of the data cut-off, HP-001 has been well-tolerated with no dose-limiting toxicities (DLTs). The most common G≥3 TRAE (≥10%) included neutropenia (G3: 34.8%, G4: 34.8%), leukopenia (G3: 26.1%, G4: 17.4%), lymphopenia (G3: 21.7%, G4: 8.7%), infection (21.7%, all G3), and thrombocytopenia (13.0%, all G3). Of interest, only 1 case of G3 anemia was reported. All these TRAEs can be managed and reversed with appropriate management strategies and follow-up.
Among the 15 efficacy-evaluable pts with R/R MM (median follow-up 7.82 months), the overall response rate (≥ partial response) is 53.3% and ≥VGPR is 33.3% (1 sCR, 2 CRs, and 2 VGPRs). The median time to response (TTR) is 1.18 month (1.01, 1.77). For the 9 pts received ≥ 0.4 mg HP-001, the ORR is 66.7% and ≥CR is 33.3%.
PK of HP-001 exposure generally appeared to increase in a dose proportional manner. At all dose levels, HP-001 has resulted in rapid and sustained degradation of both IKZF1 and IKZF3 in a dose proportional manner; at 0.6 mg, the maximum degradation of IKZF1/3 was nearly complete.
Conclusions: Preliminary results from this ongoing phase 1 trial of HP-001 in pts with hematological malignancies demonstrate that HP-001 produces responses in MM with favorable tolerability as a single agent, with a 53.3% response rate in R/R MM population. Dose expansion will continue until the recommended phase 2 doses are identified. Updated data will be presented at the conference.